Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Lev

Showing results (111-120 of 118) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 118 results.
Scientific Reports|February 14, 2020
Publisher Correction: Multiple concomitant mechanisms contribute to low platelet count in patients with immune thrombocytopeniaMatías Grodzielski, Nora P Goette, Ana C Glembotsky, et al.
Scientific Reports|February 20, 2019
Multiple concomitant mechanisms contribute to low platelet count in patients with immune thrombocytopeniaMatías Grodzielski, Nora P Goette, Ana C Glembotsky, et al.
Haematologica|June 5, 2025
Acquired Bernard-Soulier syndrome as the presenting feature of GATA2-related myeloid neoplasm in an adolescent: an insight into the mechanisms underlying the platelet defectLaureano J Kamiya, María D Morell, Rosana F Marta, et al.
Platelets|November 22, 2021
Pathogenic mechanisms contributing to thrombocytopenia in patients with systemic lupus erythematosusM Constanza Baroni Pietto, Paola R Lev, Ana C Glembotsky, et al.
Frontiers in Immunology|November 30, 2023
High cell-free DNA is associated with disease progression, inflammasome activation and elevated levels of inflammasome-related cytokine IL-18 in patients with myelofibrosisGeraldine De Luca, Paola R Lev, Maria F Camacho, et al.
Clinical Pharmacokinetics|November 28, 2025
Correction: Population Pharmacokinetics Analysis of Infliximab in up to 10‑Year‑Old Patients with Paediatric Inflammatory Bowel Disease: Label‑Recommended Dose Fails to Achieve Therapeutic Target ConcentrationQ Zhao, M M E Jongsma, S A Vuijk, et al.
Clinical Pharmacokinetics|October 29, 2025
Population Pharmacokinetics Analysis of Infliximab in up to 10-Year-Old Patients with Paediatric Inflammatory Bowel Disease: Label-Recommended Dose Fails to Achieve Therapeutic Target ConcentrationQ Zhao, M M E Jongsma, S A Vuijk, et al.
Frontiers in Immunology|October 11, 2024
Elevated levels of damage-associated molecular patterns HMGB1 and S100A8/A9 coupled with toll-like receptor-triggered monocyte activation are associated with inflammation in patients with myelofibrosisGeraldine De Luca, Nora P Goette, Paola R Lev, et al.
Pageof 12

Showing results (111-120 of 118) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 118 results.
Scientific Reports|February 14, 2020
Publisher Correction: Multiple concomitant mechanisms contribute to low platelet count in patients with immune thrombocytopeniaMatías Grodzielski, Nora P Goette, Ana C Glembotsky, et al.
Scientific Reports|February 20, 2019
Multiple concomitant mechanisms contribute to low platelet count in patients with immune thrombocytopeniaMatías Grodzielski, Nora P Goette, Ana C Glembotsky, et al.
Haematologica|June 5, 2025
Acquired Bernard-Soulier syndrome as the presenting feature of GATA2-related myeloid neoplasm in an adolescent: an insight into the mechanisms underlying the platelet defectLaureano J Kamiya, María D Morell, Rosana F Marta, et al.
Platelets|November 22, 2021
Pathogenic mechanisms contributing to thrombocytopenia in patients with systemic lupus erythematosusM Constanza Baroni Pietto, Paola R Lev, Ana C Glembotsky, et al.
Frontiers in Immunology|November 30, 2023
High cell-free DNA is associated with disease progression, inflammasome activation and elevated levels of inflammasome-related cytokine IL-18 in patients with myelofibrosisGeraldine De Luca, Paola R Lev, Maria F Camacho, et al.
Clinical Pharmacokinetics|November 28, 2025
Correction: Population Pharmacokinetics Analysis of Infliximab in up to 10‑Year‑Old Patients with Paediatric Inflammatory Bowel Disease: Label‑Recommended Dose Fails to Achieve Therapeutic Target ConcentrationQ Zhao, M M E Jongsma, S A Vuijk, et al.
Clinical Pharmacokinetics|October 29, 2025
Population Pharmacokinetics Analysis of Infliximab in up to 10-Year-Old Patients with Paediatric Inflammatory Bowel Disease: Label-Recommended Dose Fails to Achieve Therapeutic Target ConcentrationQ Zhao, M M E Jongsma, S A Vuijk, et al.
Frontiers in Immunology|October 11, 2024
Elevated levels of damage-associated molecular patterns HMGB1 and S100A8/A9 coupled with toll-like receptor-triggered monocyte activation are associated with inflammation in patients with myelofibrosisGeraldine De Luca, Nora P Goette, Paola R Lev, et al.
Pageof 12